China: Life Sciences, Biotechnology & Nanotechnology

In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...

Anti-corruption has remained an area of focus area for Chinese authorities in the first half of 2025, with major legislative updates and enforcement cases.

With the rapid development of biotechnology, the number of patent applications for biological materials such as microorganisms and cell lines has been on the rise. However, due to the unique characteristics of biological materials, they face many unique challenges in the process of patent protection

On 29 December 2023, the Standing Committee of the National People's Congress issued a major update to the current PRC Company Law. The revised PRC Company Law will enter into effect on 1 July 2024.

The National Medical Products Administration ("NMPA") issued the Circular on the Work Relating to the Implementation of GB 9706.1-2020 and Supporting Concurrent Standards and Special Standards

On 3 April 2024, the National Medical Products Administration ("NMPA") released the Notice on Further Strengthening the Supervision and Management of Entrusted Manufacturing...

デンマークに本拠を置くバイオ技術企業のノボネシス（Novonesis）社は、産業用酵素の世界トップメーカーであるノボザイムズと、乳酸菌スター

Last night, the House of Representatives passed the BIOSECURE Act (BIOSECURE or the Act) by a bipartisan vote of 306 to 81.

人工智能和脑科学的交叉融合发展为机器智能与人类智能的融合提供了可能，在全球瞩目下，脑机接口技术在医疗场景的应用处在变革前夕，